Drug Search Results
More Filters [+]

DE-110

Alternative Names: de-110, de110, de 110
Latest Update: 2024-05-10
Latest Update Note: PubMed Publication

Product Description

For corneal disease (dry eye) (Sourced from: https://www.santen.com/en/assets/pdf/ir/document/mtg2011to2013.pdf)

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DE-110

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01239069

P2

Completed

Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes

2011-10-01

Recent News Events